Safety and Tolerability of INP105 (Olanzapine by I231 POD® Device) Nasal Spray in Healthy Volunteers

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

38 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-08-05

Study Completion Date

2018-10-03

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of INP105, which is an investigational drug-device combination product comprised of the drug component OLZ administered by a Precision Olfactory Delivery (POD®) nasal spray device (I231 POD® Device). The proposed indication for INP105 is the treatment of acute agitation associated with schizophrenia and bipolar I disorder.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study of Olanzapine in Patients With Schizophrenia

NCT00970281

Schizophrenia

COMPLETED PHASE3

Pharmacokinetic Characterization of Intramuscular Olanzapine Depot

NCT00094640

Schizophrenia Schizoaffective Disorder

COMPLETED PHASE1

Safety, Tolerability, and Pharmacokinetics of Iloperidone Depot in Schizophrenic Patients

NCT01348100

Schizophrenia

COMPLETED PHASE1/PHASE2

Olanzapine Given in Combination With Zonisamide SR to Prevent Weight Gain in Schizophrenic Subjects

NCT00734435

Schizophrenia Schizoaffective Disorder Schizophreniform Disorder

TERMINATED PHASE2

Comparing the Effect of Under the Tongue Olanzapine Versus Swallowed Olanzapine on Body Mass Index (A Ratio of Weight to Height)

NCT00303602

Schizophrenia Schizoaffective Disorder Bipolar Disorder

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a randomized, double-blind, placebo- and active-controlled, ascending-dose, 2-way, 2- period, incomplete block, crossover, Phase 1 trial to compare the safety, tolerability, PK and PD of 3 single doses of INP105 with the safety, tolerability, PK and PD of 1 dose of Zyprexa IM (5 mg) and 1 dose of oral Zyprexa Zydis (10 mg). Randomization for Periods 1 and 2 will occur for each subject on Day 1.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Agitation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Period 1 (n=36) assignment to 1 of 2 reference therapy treatment groups over 3 cohorts Period 2 (n=36) assignment to 1 of 3 IP treatment groups over 3 cohorts

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Double-blind, placebo-controlled

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Period 1

Period 1 (n=36) assignment to 1 of 2 reference therapy treatment groups (Zyprexa 5mg IM or Zydis 10mg orally disintegrating wafer, 10mg) over 3 cohorts (single dose)

Group Type ACTIVE_COMPARATOR

Zyprexa IM

Intervention Type DRUG

5mg

Zydis

Intervention Type DRUG

10mg orally disintegrating wafer

Period 2

Period 2 (n=36) assignment to 1 of 3 IP treatment groups (INP105 of 5, 10, or 20mg or placebo) administered with the I231 POD® Device) over 3 cohorts (single dose)

Group Type EXPERIMENTAL

INP105

Intervention Type DRUG

Single, ascending doses of 5, 10, or 20mg capsules OLZ (olanzapine) or placebo (MCC)

I231 POD® Device

Intervention Type DEVICE

Precision Olfactory Delivery (POD) device

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Zyprexa IM

5mg

Intervention Type DRUG

Zydis

10mg orally disintegrating wafer

Intervention Type DRUG

INP105

Single, ascending doses of 5, 10, or 20mg capsules OLZ (olanzapine) or placebo (MCC)

Intervention Type DRUG

I231 POD® Device

Precision Olfactory Delivery (POD) device

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Zyprexa Zydis OLZ or placebo POD®

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Adult male (N=at least 9) and female (N=at least 9) 18 to 55 years of age (inclusive) at Screening, in good general health, with no significant medical history and no clinically significant abnormalities on physical examination at Screening or before first dose of IP.
2. Subjects must have a Body Mass Index (BMI) between 18 and 32 kg/m2 inclusive.
3. Negative urine drug screen/alcohol breath test at Screening and Day -1. Repeat tests may be performed if false positive results are suspected.
4. Subjects must have the ability and willingness to attend the necessary visits at the study centre.
5. Written informed consent signed prior to entry into the study.
6. Female subjects of childbearing potential, and male subjects and their partners, must agree to use adequate contraception, defined as complete abstinence, documented evidence of surgical sterilization or condom plus approved contraceptive method

Exclusion Criteria

1. Known hypersensitivity to Zyprexa IM, Zyprexa Zydis or any of the ingredients in them or in INP105 or the placebo.
2. Recently (within 3 months) or currently taking Zyprexa (any formulation).
3. Subjects taking medications known to inhibit or induce CYP1A2 at any time during the study period, and any subjects taking prescription medications, over the counter medications or supplements that, in the opinion of the Investigator, may impact the subject's response to INP105 or impact the subject's participation in the study. Oral contraceptives are permitted.
4. Subjects with medical history of hypotension or currently taking anti-hypertensives at Screening or throughout the study.
5. Current or recent smokers (\<3 months since quitting); inadvertent one-off smokers and social smokers will also be excluded.
6. Females who are pregnant or lactating.
7. Subjects with any underlying physical or psychological medical condition that, in the opinion of the Investigator, would make it unlikely that the subject will comply with the study.
8. Abnormal and clinically significant laboratory test results.
9. History or presence of alcohol or drug abuse within the 2 years prior to the first IP administration.
10. Blood donation or significant blood loss within 60 days prior to the first IP administration.
11. Plasma donation within 7 days prior to the first IP administration.
12. Administration of IP in another trial within 30 days or 5 half-lives (whichever is longer) prior to the first IP administration.
13. Significant surgery within the past 3 months prior to the first IP administration determined by the Investigator to be clinically relevant.
14. Failure to satisfy the Investigator of fitness to participate for any other reason.
15. Acute illness within 30 days prior to Day 1. Subjects with minor viral illnesses (for example, upper respiratory tract infection) within 30 days prior to Day 1 may be randomized if all symptoms are resolved by admission and at the discretion of the Investigator.
16. Any nasal congestion, deviated septum, or physical blockage in either nostril.
17. Positive for human immunodeficiency virus (HIV), Hepatitis B or Hepatitis C

Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes